Medicine and Dentistry
Neoplasm
100%
Nodular Melanoma
68%
Immune Checkpoint Inhibitor
65%
Metastatic Melanoma
40%
Malignant Neoplasm
36%
Ovarian Cancer
34%
Breast Cancer
31%
Overall Survival
30%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
25%
Positron Emission Tomography
23%
Programmed Cell Death
22%
Targeted Therapy
22%
BRCA1
22%
Oncology
22%
Disease
21%
Systemic Therapy
19%
Recurrent Disease
19%
Brain Metastasis
19%
Krukenberg Tumor
19%
Solid Malignant Neoplasm
19%
Positron Emission Tomography-Computed Tomography
18%
Glucose Uptake
16%
Cancer Cell
15%
Immunotherapy
15%
Fluorine-18
15%
Zirconium 89
15%
Recurrent Ovarian Cancer
15%
Polyp
15%
Glycon
15%
Progression Free Survival
14%
Adverse Event
14%
Radioactive Tracer
14%
Merkel Cell Carcinoma
14%
Quality of Life
14%
Dysplasia
13%
Non Small Cell Lung Cancer
13%
Serous Carcinoma
13%
Germ Cell
13%
Adenoma
13%
Pembrolizumab
13%
Colorectal Tumor
12%
Cancer Therapy
11%
Systematic Review
11%
Molecular Imaging
11%
Maturity Onset Diabetes of the Young
11%
Melanoma
10%
Side Effect
10%
COVID-19
10%
Beta-Catenin
10%
Treatment Response
10%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
58%
Immune Checkpoint Inhibitor
49%
Melanoma
49%
Malignant Neoplasm
36%
Disease
31%
Metformin
24%
Breast Cancer
24%
Immunotherapy
20%
Solid Malignant Neoplasm
18%
Adverse Event
17%
Overall Survival
15%
Everolimus
15%
Carboplatin
15%
Metastatic Melanoma
14%
Non Insulin Dependent Diabetes Mellitus
13%
Chemotherapy
12%
Cohort Study
11%
Ovary Cancer
11%
Progression Free Survival
10%
Tracer
10%
Paclitaxel
10%
Placebo
10%
Non-Steroidal Anti-Inflammatory Drug
10%
Human Study
10%
Brain Metastasis
10%
Veliparib
10%
Skin Cancer
10%
Colorectal Cancer
9%
Skin Carcinoma
9%
Merkel Cell Carcinoma
9%
Monoclonal Antibody
8%
Zirconium 89
8%
Myocarditis
8%
Comorbidity
8%
Ipilimumab
8%
Ovary Carcinoma
7%
Pharmacokinetics
7%
Tumor Necrosis Factor Related Apoptosis Inducing Ligand
6%
Nivolumab
6%
Biological Marker
6%
Side Effect
6%
Tumor Microenvironment
6%
Hyperglycemia
6%
Clinical Trial
6%
Cemiplimab
5%
Combination Drug
5%
Non Melanoma Skin Cancer
5%
Colon Cancer
5%
Dichloroacetic Acid
5%
Drug Intolerance
5%
Keyphrases
Immune Checkpoint Inhibitors
50%
Metastatic Melanoma
29%
Advanced Melanoma
25%
Dutch
18%
Targeted Therapy
16%
Brain Metastases
14%
Overall Survival
14%
Melanoma
12%
Pembrolizumab
12%
Tumor-like Lesions
11%
Neoadjuvant
10%
Germline Pathogenic Variant
10%
BRCA1, BRCA2
10%
High-grade Serous Carcinoma
10%
Risk-reducing Salpingo-oophorectomy
10%
Ovarian Cancer Patients
10%
Zirconium-89 (89Zr)
10%
Stage III Melanoma
10%
Phase I Study
10%
Immune Checkpoint Inhibitor Treatment
10%
Ipilimumab
9%
Positron Emission Tomography
8%
Partial Response
8%
Complete Response
8%
Patients with Cancer
8%
Melanoma Brain Metastases
8%
Programmed Death-ligand 1 (PD-L1)
7%
Disease Pattern
7%
Ovarian Cancer
7%
Tumor Response
7%
Positron Emission Tomography-computed Tomography (PET-CT)
7%
Nivolumab
7%
Immune Checkpoint Inhibitor Therapy
7%
Melanoma Patients
7%
Adverse Events
7%
Quality of Life
6%
Health-related Quality of Life
6%
Oncology
6%
18F-FDG PET-CT
6%
Treatment Response
6%
Netherlands
6%
Long-term Survival
6%
Disease-free Survival
6%
Tumor Uptake
6%
Tracer Uptake
6%
Groningen
6%
Treatment Outcome
6%
Checkpoint Inhibitors
6%
Cancer Diagnosis
6%
Cancer Treatment
6%
